1. Home
  2. OPTN

as 12-18-2024 10:41am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Founded: 2010 Country:
United States
United States
Employees: N/A City: YARDLEY
Market Cap: 78.4M IPO Year: 2017
Target Price: $3.00 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.29 EPS Growth: N/A
52 Week Low/High: $0.32 - $2.10 Next Earning Date: 11-12-2024
Revenue: $75,672,000 Revenue Growth: 5.13%
Revenue Growth (this year): 13.42% Revenue Growth (next year): 52.99%

OPTN Daily Stock ML Predictions

Share on Social Networks: